Drug Discovery Collaboration For Spinal Muscular Atrophy Expanded

Armen Hareyan's picture
Advertisement

Families of Spinal Muscular Atrophy (FSMA) and Paratek Pharmaceuticals, Inc. today announced they have extended their joint R&D collaboration to develop a drug candidate for the treatment of Spinal Muscular Atrophy (SMA), the leading genetically inherited cause of death of children under the age of two years.

The collaboration is focused on optimizing and advancing into the clinic a novel small molecule within Paratek's library derived from the tetracycline class of compounds.

Advertisement